<DOC>
	<DOC>NCT02018172</DOC>
	<brief_summary>The study is performed to collect long-term data on the treatment adherence and patient's acceptability when Zomacton®10 mg is administered with the Zomajet® Vision X device in patients with a growth hormone deficiency or Turner's syndrome.</brief_summary>
	<brief_title>Evaluation of the Adherence and the Patient Acceptability of Zomacton® Treatment With the Zomajet® Vision X Device</brief_title>
	<detailed_description />
	<mesh_term>Dwarfism, Pituitary</mesh_term>
	<mesh_term>Turner Syndrome</mesh_term>
	<mesh_term>Gonadal Dysgenesis</mesh_term>
	<mesh_term>Primary Ovarian Insufficiency</mesh_term>
	<criteria>Patient with growth hormone deficiency, 1. Diagnosis of growth hormone deficiency proven by appropriate exploration 2. Size ≤ 2 Standard Deviation (SD) according to the French references 3. Growth velocity in the previous year inferior to the normal for age (1SD) or &lt; 4cm/year Growth deficiency due to Turner's syndrome 1. Turner's syndrome confirmed by a karyotype 2. Patient's size ≤ 2 SD according to the French references 3. Bone age &lt; 12 years Patient who require a minimum of 18 months of treatment. There are no exclusion criteria except the contraindication for Zomacton® 10 mg</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>